HT
AMRX icon

Headlands Technologies’s Amneal Pharmaceuticals AMRX Stock Holding History

Headlands Technologies’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$255K Sell
20,478
-41,247
-67% -$554K 0.03% 542
2025
Q4 		$778K Buy
61,725
+21,357
+53% +$244K 0.06% 311
2025
Q3 		$404K Buy
40,368
+15,676
+63% +$141K 0.03% 407
2025
Q2 		$200K Buy
24,692
+21,007
+570% +$158K 0.02% 469
2025
Q1 		$30.9K Buy
+3,685
New +$30.8K ﹤0.01% 791

Other funds holding AMRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Headlands Technologies's AMRX Position: Q1 2026 in Review

Headlands Technologies reduced its Amneal Pharmaceuticals (AMRX) stake by 67% in Q1 2026, selling an estimated $554K and leaving 20,478 shares worth $255K. The position accounts for 0.03% of the portfolio, ranked #542.

Headlands Technologies first reported a position in AMRX in Q1 2025 and has held it in 5 quarters since. The position peaked at $778K in Q4 2025. 316 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Headlands Technologies held 20,478 shares of Amneal Pharmaceuticals worth $255K as of Q1 2026.
  • Headlands Technologies sold 41,247 Amneal Pharmaceuticals shares in Q1 2026, an estimated $554K.
  • Amneal Pharmaceuticals made up 0.03% of Headlands Technologies's portfolio in Q1 2026, its #542 holding.
  • Headlands Technologies first reported a position in Amneal Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Headlands Technologies's Amneal Pharmaceuticals position peaked at $778K in Q4 2025.
  • 316 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.